

AD _____

AWARD NUMBER: W81XWH-12-1-0191

TITLE:

“Vt gcw gpv'cpf 'Rt gxgp wqp 'qhDt gcw'Ecpegt 'Wulpi 'O wnlwpe wqp c nKj kkkqt u'qhEj qngugt qn' Dkqu(pvj guki’

PRINCIPAL INVESTIGATOR:

Salman Hyder, PhD

RECIPIENT:

University of Missouri, Columbia
Columbia, Missouri 65211-1230

REPORT DATE:

June 2014

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE June 2014		2. REPORT TYPE Annual		3. DATES COVERED 1 June 2013 - 31 May 2014	
4. TITLE AND SUBTITLE "Treatment and Prevention of Breast Cancer Using Multifunctional Inhibitors of Cholesterol Biosynthesis"				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0191	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Salman Hyder, PhD email: hyders@missouri.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Missouri, Columbia Columbia, Missouri 65211-1230				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Most human breast cancers are hormone responsive, depending on estrogens and progestins for tumor cell proliferation. Initially, hormone-responsive tumors respond to endocrine therapy, however, most human breast tumors develop resistance to currently used endocrine therapeutic protocols. It is therefore essential that we identify additional molecular targets in the signaling pathways that lead to tumor growth if we are to effectively treat and prevent cancers of the breast. Our goal was to identify alternative targets in the pathway leading to the production of cholesterol, which might be regulated with less toxic inhibitors to control the progression of breast disease. Inhibitors of oxidosqualene cyclase (OSC), an enzyme down-stream of HMG CoA-reductase in the cholesterol biosynthetic pathway, effectively arrested breast cancer cell proliferation. In the 2013 Annual Report we discussed several interesting observations establishing that an OSC inhibitor, RO 48-8071 (RO) is an effective anti-cancer compound. These results are now published and appended as a research article in Breast Cancer Research and Treatment, a highly reputable journal. During our second year of research we have continued these studies and shown that combination therapy involving RO and an estrogen receptor-beta agonist is an extremely effective means of treating breast cancer. We found that estrogen receptor beta is induced and, importantly, that the pro-proliferative estrogen receptor-alpha is destroyed by RO. These studies show for the first time that inhibition of cholesterol biosynthesis using OSC inhibitors is a novel and potent means by which to destroy human breast cancer cells, and, furthermore, that a combination of RO with agonists of estrogen receptor beta is a viable treatment option that should be considered for patients who exhibit estrogen receptor in their biopsies. Finally, in the past year we have also established that RO controls not only the activity of estrogen receptor, but also androgen receptor activity. These results are attached and are of particular importance considering that androgen receptor is regarded as a target for triple negative breast cancers for which there are few options available to control the progression of this deadly disease.					
15. SUBJECT TERMS- none provided					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	43	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Overall Project Summary	4
4. Key Research Accomplishments	6
5. Conclusion	7
6. Publications, Abstracts, and Presentations	7
7. Inventions, Patents and Licenses	7
8. Reportable Outcomes	8
9. Other Achievements	8
10. References	9
11. Appendices	11-End

1. **INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

The purpose of this research is to investigate whether an inhibitor of cholesterol synthesis (RO) is also an effective therapeutic drug which can be used to control the progression of breast cancer. The effects of RO on a number of different breast cancer cell lines have been examined, as well as its in vivo effect against breast cancer cells grown in xenograft models. Protocols in which the inhibitor is given alone or in combination with other compounds have been employed. Initial results were reported last year. These have now been published and the manuscript is appended. During the past 12 months intensive studies to determine the effectiveness of combination therapy using RO and estrogen receptor beta agonists have been performed. The results are reported herein. In addition, efforts have been made to determine whether RO influences the transcriptional activities of estrogen receptor.

2. **KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

Breast Cancer, Cholesterol inhibitors, therapeutics, Cell viability, apoptosis, estrogen receptor beta, combination therapy, transcriptional activity, androgen receptor.

3. **OVERALL PROJECT SUMMARY:** Summarize the progress during appropriate reporting period (single annual or comprehensive final). This section of the report shall be in direct alignment with respect to each task outlined in the approved SOW in a summary of Current Objectives, and a summary of Results, Progress and Accomplishments with Discussion. Key methodology used during the reporting period, including a description of any changes to originally proposed methods, shall be summarized. Data supporting research conclusions, in the form of figures and/or tables, shall be embedded in the text, appended, or referenced to appended manuscripts. Actual or anticipated problems or delays and actions or plans to resolve them shall be included. Additionally, any changes in approach and reasons for these changes shall be reported. **Any change that is substantially different from the original approved SOW (e.g., new or modified tasks, objectives, experiments, etc.) requires review by the Grants Officer's Representative and final approval by USAMRAA Grants Officer through an award modification prior to initiating any changes.**

Progress related to Task 1. *Characterize the impact of RO on estrogen signaling in breast cancer cells. (estrogen receptor alpha=ER α ; estrogen receptor beta=ER β)*

Goals:

- a. Determine the effect of RO therapy on cell viability using a number of different breast cancer cells, and normal mammary cells.
- b. Determine the level of ER α and ER β expression in treated cells by Western blot analysis.
- c. Determine the effect of RO treatment on estrogen-dependent proliferation of breast cancer cells.

- d. Determine whether RO treated ER α positive cells lose their capacity to regulate ER α -dependent gene regulation but retain the ability to regulate ER β specific genes with ER β -interacting ligands.
- e. Determine whether RO influences transcription of ER α and ER β genes in breast cancer cells.
- f. Determine whether RO influences stability of ER α and ER β protein in breast cancer cells.

This aim is mostly complete and a manuscript describing the results has been published (appendix). A recently presented abstract at the Annual Endocrine Society Meeting is also appended. In the last year we addressed point e. above and showed that RO influences the transcriptional effects of estrogen receptor, and surprisingly, of androgen receptor as well. These results are reported in attached Figs 1-6. A manuscript describing this data is currently in preparation.

Progress related to Task 2. *Characterize the in vitro effects of RO mono- or combination therapy on proliferation and apoptosis of breast cancer cells in vitro.*

Goals:

- a. Measure apoptosis in breast cancer cells treated with RO alone or RO in combination with ER β interacting ligands.
- b. Determine protein levels of apoptosis related genes (p21, caspase-3, Bcl-2, Bad, Bax) following treatment of cells with RO.
- c. Initiate combination therapy, keeping the concentration of one ligand constant while varying that of the other to determine whether there are additive or synergistic effects on apoptosis.
- d. Determine mRNA and protein levels of proteins related to apoptosis and angiogenesis, such as p21, caspase-3, Bcl-2, Bad, Bax, and VEGF following treatment of cells with RO in combination with aforementioned compounds.
- e. Transfect cells with siRNA to down-regulate ER β and determine cell viability and response to RO using cell-proliferation assays.
- f. Following ER β and OSC siRNA transfections, test breast cancer cells for lack of sensitivity to RO in order to define a molecular target for mediating RO effects. These experiments will utilize cell viability assays.

A number of studies described in task 2 have been completed and also reported in the attached manuscript. However in the last year we have spent considerable effort to address point c. above and study the effect of combination therapy. Please see attached Figures 7-10 for results obtained. As indicated in task 3, we are making progress with our studies to determine the in vivo effects of combination therapy for controlling breast cancer progression and we have obtained a no-cost extension from DOD officials to continue since more time is needed if we are to elucidate the mechanism behind our observations (also see task 3).

Progress related to Task 3. *Characterize the effects of RO mono- or combination therapy on progression and prevention of breast cancer cells in vivo in rodent models.*

Goals:

- a. Breast cancer cells in matrigel will be inoculated into nude mice (6-8 week-old, female, nu/nu, sc).
- b. Tumors will be allowed to reach 100-200mm³ in size, after which animals will be randomly assigned to groups for treatment with RO or vehicle alone. RO treatment (5-25 mg/kg, iv) will be once a day for 10 days.
- c. Experiment in b) will be repeated in vivo using a combination of RO and an ER β specific ligand, as well as RO and a natural compound with an affinity for ER β , to determine additive or synergistic effects in reducing in vivo tumor progression.
- d. Tumor samples will be collected after the first three injections and then again at the end of the experiment in b. and c. for further analysis by immunohistochemistry. Samples will also be saved in liquid nitrogen for Western blot analysis and RNA isolation.
- e. Western Blot and RT-PCR will be used to analyze protein levels and RNA expression of ER, PR, p21, Caspase-3 and VEGF.
- f. Immunohistochemistry will be used to quantitate blood vessel density and various antigens indicated in e.

In vivo studies using RO are underway. We have already shown in our previous report that RO is effective against breast cancer (manuscript attached). We now have robust data from experiments conducted in the last year showing that combination therapy with RO and an estrogen receptor beta ligand is an efficient way to treat both hormone-dependent and hormone-independent breast cancers without toxicity (Fig 7A-B). We conducted in vitro combination therapy and utilized liquiritigenin, an ER β interacting ligand which was most effective in vitro, in our subsequent in vivo studies. These experiments are reported in Figs 7-10. We have taken a one-year no-cost extension to complete immunohistochemical analysis of tumor tissue and determine the mechanism for such a powerful anti-tumor effect. A few other studies in tasks 1 and 2 will also be finalized during the no-cost extension.

4. KEY RESEARCH ACCOMPLISHMENTS: Bulleted list of key research accomplishments emanating from this research. Project milestones, such as simply completing proposed experiments, are not acceptable as key research accomplishments. Key research accomplishments are those that have contributed to the major goals and objectives and that have potential impact on the research field.

- OSC expression is not associated with stage of breast disease
- RO blocks transcriptional activities of both estrogen and androgen receptors
- RO blocks estrogen receptor alpha more strongly than estrogen receptor-beta
- RO competes with estrogen for binding to the estrogen receptor though at much higher concentrations, suggesting an allosteric modification of estrogen receptor
- RO blocks the production of an estrogen regulated gene (progesterone receptor) in breast cancer cells
- RO does not regulate estrogen receptor at the transcriptional level
- RO in combination with estrogen receptor beta interacting agonists is a powerful combination which stops the progression of breast tumors both in vitro and in vivo

- 5. CONCLUSION:** Summarize the importance and/or implications with respect to medical and /or military significance of the completed research including distinctive contributions, innovations, or changes in practice or behavior that has come about as a result of the project. A brief description of future plans to accomplish the goals and objectives shall also be included.

Our research, with the support of this grant, shows that inhibitors of cholesterol synthesis that target OSC induce tumor cell apoptosis and can therefore be used to prevent the progression of breast cancer cells. In addition OSC inhibitors have off-target effects; they degrade estrogen receptor alpha, a major pro-proliferative protein in hormone-responsive cells, and induce estrogen receptor beta protein, a major factor which reduces cell proliferation. The results pertaining to combination therapy involving RO and estrogen receptor beta interacting ligands are particularly interesting and important since they potentially support the use of lower levels of toxic chemotherapeutic drugs together with RO to bring about tumor regression. Once the studies proposed in the grant are complete, they will yield information vital to determining the suitability of these drugs for use in humans. We propose that it is important to move forward with human clinical trials which we believe could set the stage for the therapeutic use of OSC inhibitors against breast cancer, and potentially save millions of lives worldwide.

6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

- a. List all manuscripts submitted for publication during the period covered by this report resulting from this project. Include those in the categories of lay press, peer-reviewed scientific journals, invited articles, and abstracts. Each entry shall include the author(s), article title, journal name, book title, editors(s), publisher, volume number, page number(s), date, DOI, PMID, and/or ISBN.

(1) Lay Press:

<http://munews.missouri.edu/news-releases/2014/0617-potential-cholesterol-lowering-drug-has-breast-cancer-fighting-capabilities-mu-researcher-finds/>

(2) Peer-Reviewed Scientific Journals:

Liang Y, Besch-Williford C, Aebi JD, Mafuvadze B, Cook MT, Zou X, Hyder SM. (2014) [Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071](#). Breast Cancer Res Treat. 146:51-62.

(3) Invited Articles:

Hyder, S. M., Mafuvadze, B and Besch-Williford, C. (2013) Novel Anti-Angiogenic Therapies using Naturally-Occuring and Synthetic Drugs to Combat Progestin-Dependent Breast Cancer to be published in Cell and Molecular Biology of Breast Cancer, Humana Press, In Press

(4) Abstracts:

Liang, Y., Zou, X., Besch-Williford, C., Johnnes, A. and Hyder, S. M. (2013) Synthetic inhibitors of the cholesterol biosynthetic enzyme oxidosqualene cyclase block proliferation and survival of breast cancer cells. 103rd Annual American Association of Cancer Research Meeting, Washington DC, USA, Abstract #871

Mafuvadze, B., Liang, Y., Hyder, S. M. (2014) Oxidosqualene Cyclase Inhibitor Suppresses Transcriptional Activity of Estrogen Receptor- α in Human Breast Cancer Cells. 16th International Congress of Endocrinology and the Endocrine Society's 96th Annual Meeting and Expo, Chicago, IL. Abstract SAT-0279

- b. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.

*Liang, Y., Zou, X., Besch-Williford, C., Johannes, A. and Hyder, S. M. (2013) Synthetic inhibitors of the cholesterol biosynthetic enzyme oxidosqualene cyclase block proliferation and survival of breast cancer cells. 103rd Annual American Association of Cancer Research Meeting, Washington DC, USA, Abstract #871

Mafuvadze, B., Liang, Y., Hyder, S. M. (2014) Oxidosqualene Cyclase Inhibitor Suppresses Transcriptional Activity of Estrogen Receptor- α in Human Breast Cancer Cells. 16th International Congress of Endocrinology and the Endocrine Society's 96th Annual Meeting and Expo, Chicago, IL. Abstract SAT-0279

- 7. INVENTIONS, PATENTS AND LICENSES:** List all inventions made and patents and licenses applied for and/or issued. Each entry shall include the inventor(s), invention title, patent application number, filing date, patent number if issued, patent issued date, national, or international.

Nothing to report

- 8. REPORTABLE OUTCOMES:** Provide a list of reportable outcomes that have resulted from this research. Reportable outcomes are defined as a research result that is or relates

to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. This list may include development of prototypes, computer programs and/or software (such as databases and animal models, etc.) or similar products that may be commercialized.

All the results described in Section 3 are reportable. Some of these have been published (attached manuscript), and additional data will soon be published. The results show a substantial advance towards a potentially new therapeutic protocol for breast cancer which could involve the use of specific cholesterol lowering drugs that target oxidosqualene cyclase. These drugs may be administered with or without additional drugs that target estrogen signaling mechanisms. Evidence for such a possibility comes from our observation that estrogen receptor beta specific ligands appear to enhance the effects of cholesterol lowering drugs. It is possible that such an approach could also prove useful for preventing breast cancer in the first place.

- 9. OTHER ACHIEVEMENTS:** This list may include degrees obtained that are supported by this award, development of cell lines, tissue or serum repositories, funding applied for based on work supported by this award, and employment or research opportunities applied for and/or received based on experience/training supported by this award.

Nothing to report

For each section, 4 through 9, if there is no reportable outcome, state “Nothing to report.”

- 10. REFERENCES:** List all references pertinent to the report using a standard journal format (i.e., format used in *Science*, *Military Medicine*, etc.).

n/a

- 11. APPENDICES:** Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

Please see attached

NOTE:

TRAINING OR FELLOWSHIP AWARDS: For training or fellowship awards, in addition to the elements outlined above, include a brief description of opportunities for training and professional development. Training activities may include, for example, courses or one-on-one work with a mentor. Professional development activities may include workshops, conferences, seminars, and study groups.

COLLABORATIVE AWARDS: For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.

QUAD CHARTS: If applicable, the Quad Chart (available on this eReceipt System https://cdmrp.org/Program_Announcements_and_Forms/ and under “Forms” on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.

MARKING OF PROPRIETARY INFORMATION: Data that was developed partially or exclusively at private expense shall be marked as “Proprietary Data” and Distribution Statement B included on the cover page of the report. Federal government approval is required before including Distribution Statement B. The recipient/PI shall coordinate with the GOR to obtain approval. REPORTS NOT PROPERLY MARKED FOR LIMITATION WILL BE DISTRIBUTED AS APPROVED FOR PUBLIC RELEASE. It is the responsibility of the Principal Investigator to advise the GOR when restricted limitation assigned to a document can be downgraded to “Approved for Public Release.” DO NOT USE THE WORD “CONFIDENTIAL” WHEN MARKING DOCUMENTS. See term entitled “Intangible Property – Data and Software Requirements” and https://mrmc.amedd.army.mil/index.cfm?pageid=researcher_resources.technical_reporting for additional information.

Figure 1: Relative OSC mRNA expression in breast cancer at different stages of growth determined using real-time PCR assay
(No significant correlation was obtained)




Figure 2: Relative OSC mRNA expression in distinct breast cancer tissues at different stages of growth (Stage I-III).

Results showed no difference in expression between ER/PR positive, ER/PR negative and triple-negative tissues (ER/PR and Her2-neu negative). *triple-negative, **ER/PR negative Her2-neu high; remaining tumors are ER/PR positive




Figure 3A-D: RO significantly inhibits estradiol induced estrogen receptor-mediated transcriptional (luciferase) activity.




Figure 3B.




Figure 3C. ICI=ICI 182,780, an anti-estrogen (antagonist)




Figure 3D. Ator=Atorvastatin




Figure 4: RO significantly inhibits androgen-induced androgen receptor activity (luciferase). OH-Flut, hydroxyflutamide, an antagonist for androgen receptor; ICI= ICI 182,780, an antagonist for estrogen receptor; Ator, Atorvastatin, a statin used for lowering cholesterol




Figure 5. RO and other compounds tested do not show toxicity effects at the concentrations used. Sta= Staurosporine, an agent that induces apoptosis and kills cells.




Figure 6A: RO inhibits estradiol –induced progesterone receptor expression in breast cancer cells. E2=Estradiol




Figure 6B: Relative estrogen receptor mRNA expression in human breast cancer cells




Fig 7A: Effect of 4-OH-Tamoxifen monotherapy on viability of different breast cancer cell lines. Note that sensitivity of MDA-MB-231 were less sensitive to tamoxifen.




Fig 7B: Effect of combination therapy using Ro 48-8071 plus Tamoxifen on viability of BT-474 and MDA-MB-231 cells. Cells were pre-treated with RO to induce estrogen receptor beta. Comparison with Fig 7A shows that combination therapy is extremely effective against these cell lines. Concentrations are in μM . *, significantly different from control group, ** significantly different from other groups (ANOVA).





Fig 8A: Effect of Liquiritigenin, an estrogen receptor beta agonist, on viability of different breast cancer cell lines.




Fig 8B: Effect of Ro 48-8071 plus Liquiritigenin on growth of estrogen receptor alpha positive breast cancer cell lines (treatment 24 h). Cells were pre-treated with RO for 3-6 h to induce estrogen receptor beta and then RO was added. Figure shows that combination therapy is extremely effective against these cell lines. Concentrations are in μM . *, significantly different from control group, ** significantly different from other groups (ANOVA).





Fig 8C: Effect of Ro 48-8071 plus Liquiritigenin on growth of estrogen receptor alpha negative breast cancer cell lines. Cells were pre-treated with RO to induce estrogen receptor beta and then treatment was continued for another 18 h. Concentrations are in μM . Combination therapy was extremely effective as shown in the figure below. *, significantly different from control group, ** significantly different from other groups (ANOVA).




Fig 9A: Effect of Ro 48-8071 combined with Liquiritigenin on in vivo growth of BT-474 xenografts. Treatment was with RO 10 mg/kg iv + Liquiritigenin 20 mg/kg ip over time period indicated. *, significantly different from control group; **, significantly different from all other groups.





Fig 9B: Animal weight during drug treatment shown in Fig 9A.



**Fig 9C: Effect of RO 48-8071 combined with
Liquiritigenin on clearance of BT-474 tumors
in vivo.**




Fig 10A: Effect of Ro 48-8071 combined with Liquiritigenin on in vivo growth of MDA-MB-231 xenografts. Treatment was with RO 10 mg/kg iv + Liquiritigenin 20 mg/kg ip over time period indicated. *, significantly different from control; ** significantly different from all other groups (ANOVA)





Fig 10B: Animal weight during drug treatment shown in Fig 10A



Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071

Yayun Liang · Cynthia Besch-Williford ·
Johannes D. Aebi · Benford Mafuvadze ·
Matthew T. Cook · Xiaoqin Zou · Salman M. Hyder

Received: 6 March 2014 / Accepted: 8 May 2014 / Published online: 31 May 2014
© Springer Science+Business Media New York 2014

Abstract In most human breast cancers, tumor cell proliferation is estrogen dependent. Although hormone-responsive tumors initially respond to anti-estrogen therapies, most of them eventually develop resistance. Our goal was to identify alternative targets that might be regulated to control breast cancer progression. Sulforhodamine B assay was used to measure the viability of cultured human breast cancer cell lines exposed to various inhibitors. Protein expression in whole-cell extracts was determined by Western blotting. BT-474 tumor xenografts in nude mice were used for in vivo studies of tumor progression. RO 48-8071 ([4'-[6-(Allylmethylamino)hexyloxy]-4-bromo-2'-

fluorobenzophenone fumarate]; RO), a small-molecule inhibitor of oxidosqualene cyclase (OSC, a key enzyme in cholesterol biosynthesis), potentially reduced breast cancer cell viability. In vitro exposure of estrogen receptor (ER)-positive human breast cancer cells to pharmacological levels of RO or a dose close to the IC₅₀ for OSC (nM) reduced cell viability. Administration of RO to mice with BT-474 tumor xenografts prevented tumor growth, with no apparent toxicity. RO degraded ER α while concomitantly inducing the anti-proliferative protein ER β . Two other cholesterol-lowering drugs, Fluvastatin and Simvastatin, were less effective in reducing breast cancer cell viability and were found not to induce ER β . ER β inhibition or knockdown prevented RO-dependent loss of cell viability. Importantly, RO had no effect on the viability of normal human mammary cells. RO is a potent inhibitor of hormone-dependent human breast cancer cell proliferation. The anti-tumor properties of RO appear to be in part due to an off-target effect that increases the ratio of ER β /ER α in breast cancer cells.

Electronic supplementary material The online version of this article (doi:10.1007/s10549-014-2996-5) contains supplementary material, which is available to authorized users.

Y. Liang · B. Mafuvadze · M. T. Cook · X. Zou ·
S. M. Hyder (✉)
Dalton Cardiovascular Research Center, University of Missouri,
Columbia, MO 65211, USA
e-mail: hyders@missouri.edu

Y. Liang · B. Mafuvadze · M. T. Cook · S. M. Hyder
Department of Biomedical Sciences, University of Missouri,
Columbia, MO 65211, USA

C. Besch-Williford
IDDEX RADIL, Columbia, MO 65202, USA

J. D. Aebi
Small Molecule Research, Medicinal Chemistry, Pharma
Research & Early Development (pRED), F. Hoffmann-La Roche
AG, Grenzacherstrasse 124, 4070 Basel, Switzerland

X. Zou
Department of Physics and Astronomy, Department of
Biochemistry, and Informatics Institute, University of Missouri,
Columbia, MO 65211, USA

Keywords Breast cancer · Tumor progression ·
Cholesterol biosynthesis inhibitors · Estrogen receptor

Abbreviations

E	Estrogen
ER	Estrogen receptor
PR	Progesterone receptor
OSC	Oxidosqualene cyclase
RO	RO 48-8071 ([4'-[6-(Allylmethylamino)hexyloxy]-4-bromo-2'-fluorobenzophenone fumarate])
FBS	Fetal bovine serum
SRB	Sulforhodamine B
PI	Propidium iodide

sc	Subcutaneous
iv	Intravenous
PBS	Phosphate-buffered saline
TBS-T	Tris-buffered saline containing 0.1 % Tween 20
ANOVA	Analysis of variance
SE	Standard error
DPN	2,3-bis(4-Hydroxyphenyl)-propionitrile
PHTPP	4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol
FACS	Fluorescence-activated cell sorting

Introduction

Estrogens (E) are essential steroid hormones that regulate sexual development and reproductive functions in humans. The diverse biological effects of E are mediated by the specific estrogen receptors (ER) ER α and ER β [1–3]. Almost 70 % of human breast tumors express both ER and progesterone receptor (PR) and proliferate in response to the respective hormone [4–6]. At the cellular level, E and progestins stimulate cell proliferation and metastasis [4–7], promote angiogenesis [8], inhibit cell death [9, 10], and increase the risk of breast cancer in post-menopausal women on hormone replacement therapy [11–14]. ER α -positive breast cancers are usually treated with anti-estrogens and aromatase inhibitors, but resistance to these agents invariably develops during the course of therapy; these drug-resistant tumors then proliferate more aggressively than the drug-sensitive tumors from which they arose [15, 16]. Therefore, novel and more effective treatment strategies that could target ERs in hormone-dependent breast cancer are urgently needed.

Enzymes in the cholesterol biosynthetic pathway are attractive therapeutic targets for hormone-dependent breast cancer, because cholesterol serves as the metabolic precursor of endogenous steroid hormones, including those found in tumors [17, 18]. In addition, breast cancer cells have the capacity to synthesize cholesterol, and it is possible that endogenously produced cholesterol could contribute to the development of anti-hormone resistance [18, 19]. Statins, which are the most commonly used class of cholesterol-lowering drug, inhibit HMG-CoA reductase, an enzyme in the cholesterol biosynthetic pathway; however, certain undesirable side effects limit their long-term use for cancer therapy [20]. 2,3-Oxidosqualene cyclase (OSC) is an enzyme that acts downstream of HMG-CoA reductase to convert 2,3-monoepoxysqualene to lanosterol (a key step in

the biosynthesis of cholesterol) [21–23]. While testing small-molecule inhibitors of OSC, we identified RO 48-8071 ([4'-[6-(Allylmethylamino)hexyloxy]-4-bromo-2'-fluorobenzophenone fumarate] (RO) [21–23] as a potent suppressor of breast tumor cell viability [24]. In the present study, we describe the anti-tumor effects of RO on ER α -positive tumors, both in vitro and in vivo. We observed that in addition to its recognized properties, RO also had off-target effects, degrading ER α while concomitantly inducing ER β , the latter of which has been shown to block proliferation of breast cancer cells [25–28] and suppress tumor angiogenesis [29]. Consistent with these findings, we found that the anti-proliferative effects of RO were blocked by an ER β -specific antagonist and ER β -targeted siRNA. RO also induced apoptosis of breast cancer cells. Thus, RO exhibits unique anti-tumor properties, making it an exciting candidate compound for clinical management of breast cancer progression when used as mono-therapy and potentially in combination with ER β -specific ligands.

Materials and methods

Cell lines and culture

ER α -positive breast cancer cell lines and normal mammary cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and grown in phenol red-free DMEM:F12 medium (Invitrogen Corporation & Life Technologies, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA).

Reagents

RO 48-8071, Fluvastatin, Simvastatin, ICI 182,780, and U1866A were purchased from Sigma-Aldrich; RO analogs were provided by Roche Pharmaceuticals (Basel, Switzerland) and were synthesized as previously described [22, 30]. MG-132 was from Calbiochem; 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN) and 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) were from Tocris Biosciences. Sixty-day release pellets containing 17- β -estradiol (1.7 mg) or placebo were obtained from Innovative Research of America (Sarasota, FL, USA). Antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), as were human ER- β -siRNA (sc-35325) and scrambled siRNA (sc-37007). LipofectamineTM, RNAiMAX, and Opti-MEM medium were obtained from Invitrogen Corporation & Life Technologies. RNazol for RNA isolation was purchased from Molecular Research (Cincinnati, OH, USA).

Cell viability assay

The sulforhodamine B (SRB) assay was used to measure cell viability, as previously described by us [31].

Cell apoptosis and death assay

Cells were analyzed for apoptosis using the Annexin V-FITC Apoptosis Detection Kit (Biovision Research Products, Mountain View, CA, USA) as previously described [32].

In vivo breast tumor growth inhibition assays

All animal experiments were approved by the Institutional Review Committee. Female athymic nude mice (nu/nu, Foxn1), 5 to 6 weeks old and weighing 20–22 g, were purchased from Harlan Sprague–Dawley, Inc. (Indianapolis, IN, USA). Mice were implanted subcutaneously (sc) with pellets containing either 17- β -estradiol (1.7 mg/pellet, 60-day release) or placebo prior to inoculation of BT-474 breast cancer cells as previously described by us [33]. Tumor volumes were measured as described previously [33], and drug treatment was started when tumor volumes reached approximately 100 mm³. Mice treated with RO received 5 or 10 mg/kg by intravenous (iv) injection of a 0.1 ml solution into the tail vein daily for 5 days, followed by an injection every other day for five additional treatments and then a final injection 2 h prior to sacrifice. Control mice received the same volume of phosphate-buffered saline (PBS) on the same schedule. Animals were weighed twice weekly throughout the study.

Tumors were collected following the last injection and processed for immunohistochemical analysis of ER α and ER β as described previously [33, 34]. Quantitation of immunolabeled signal was achieved using a morphometric analysis program (FoveaPro 3.0, Reindeer graphics), on images photographed at 20 \times magnification as described earlier [34]. 3–4 Tumors/groups were analyzed for ER signal, and 2–3 representative sections were collected from each tumor. Results are expressed as area in square pixels.

Western blots

Whole-cell extracts were prepared with a nuclear extraction TransAm kit (Active Motif, Carlsbad, CA, USA) as described previously, and Western blotting was carried out as previously described [30, 32, 33].

siRNA knockdown

ER β siRNA transfection was conducted following the manufacturers protocol (Santa Cruz). The transfection

medium used was Opti-MEM, and transfection reagent was Lipfectamine RNAiMAX. The day before transfection, cells were seeded in 6-well plates at a density of 8×10^4 cells/well with 10 % FBS DMEM:F12 medium. Cells were incubated for 24 h with siRNA, after which 1 ml fresh 10 % FBS DMEM:F12 medium was added to each well. Cells were then incubated for another 24–48 h prior to treatment with RO.

Statistical analysis

Differences between groups or among groups were tested, respectively, using one-way analysis of variance (ANOVA) with repeated measures over time. The assumption of the ANOVA was examined, and a nonparametric measure based on ranks was used if needed. Values are reported as mean \pm SEM. When ANOVA indicated a significant effect (F-ratio, $P < 0.05$), the Student–Newman–Keuls multi-range test was used to compare the means of the individual groups. Statistical analyses were conducted using SigmaStat software, version 3.5. For immunohistochemical analysis, data were analyzed using Kruskal–Wallis ANOVA, followed by Tukey's procedure as a post hoc test. For all comparisons, $P < 0.05$ was regarded as statistically significant. Values are reported as mean \pm SEM.

Results

OSC inhibitors reduce cell viability of ER α -positive breast cancer cells but not normal mammary cells

Using several ER α -positive breast cancer cells, we tested the ability of four OSC inhibitors to reduce cell viability (Fig. 1a). While all four compounds reduced cell viability, RO 48-8071 and RO 61-3479 most effectively reduced the viability of BT-474, T47-D, and MCF-7 cells in a time- and dose-dependent manner. We selected RO 48-8071 (referred to as RO from this point forward) as the lead compound for further studies. RO also effectively reduced cell viability of HCC-1428 and ZR-75 cells (Online Resource 1). The IC₅₀ values for the cell lines tested ranged from approximately 6–15 μ M in a 24–48 h SRB assay (Table 1). Because the affinity of RO for OSC is in the nM range [22, 23], we examined whether a range of low doses of RO would affect cell viability over an extended period of time (7-day assay) similar to the effects observed for higher doses over a 24-h period. We found that RO concentrations as low as 1 nM effectively reduced BT-474 and MCF-7 cell viability in 7-day assays (Fig. 1b). To determine whether RO specifically reduces cancer cell viability, leaving normal cells unaffected, we conducted studies using normal AG1132A




Fig. 1 OSC inhibitors reduce the viability of breast cancer cells but not normal mammary cells. **a** Breast cancer cells were incubated with pharmacological doses of indicated compounds for 48 h. **b** Breast cancer cells were incubated with low-dose (nM range) RO for 7 days. **c** Normal mammary cells (AG11132A) were treated with pharmacological doses of RO for 24 h and compared directly with the two

cancer cell lines shown. **d** BT-474 breast cancer cells were treated with RO or the statins Simvastatin or Fluvastatin for 24 or 48 h. Cell viability was determined by SRB assay. Values represent mean \pm SEM ($n = 6$). *Significantly different from control (set at 100 %) ($P < 0.05$ using ANOVA)

Table 1 IC_{50} values of RO 48-8071 on breast cancer cell lines

Cell lines	IC_{50} (μM) (24 h)	IC_{50} (μM) (48 h)
BT-474	9.51 ± 0.05	6.06 ± 0.23
T47-D	11.53 ± 0.36	7.76 ± 0.29
MCF-7	12.32 ± 0.59	6.34 ± 0.34
HCC-1428	14.64 ± 0.42	11.58 ± 0.34
ZR-75	11.04 ± 0.29	7.63 ± 0.30

mammary cells. Concentrations of RO up to $10 \mu\text{M}$ reduced cancer cell viability, but had no effect on normal cells (Fig. 1c).

We also compared the ability of RO to reduce breast cancer cell viability with that of two other inhibitors of cholesterol biosynthesis (statins). The HMG-CoA reductase inhibitors Simvastatin and Fluvastatin also reduced cell viability; however, RO was more effective than either statins in 24- or 48-h assays (Fig. 1d).




Fig. 2 RO induces apoptosis and cell death in breast cancer cells. **a** BT-474 and MCF-7 cells were seeded in 6-well plates overnight in 10 % FBS DMEM:F12 (1.5×10^5 /well). After washing and replacement of media, cells were treated with 5, 10, or 20 μ M RO or vehicle alone (control) for 24 h. Following treatment, cells were harvested and stained with annexin V-FITC and propidium iodide (PI).

Fluorescence-activated cell sorting (FACS) analysis of 10,000 cells/sample was conducted. Quadrant R5 (*bottom right*) shows annexin V-positive (apoptotic) cells, and quadrant R3 (*top right*) shows annexin V-positive/PI-positive (dead) cells. **b** Quantitative data from FACS analysis. Values represent mean \pm SEM ($n = 3$). *Significantly different from control ($P < 0.05$ using ANOVA)

RO induces apoptosis and cell death in breast cancer cells


In order to determine the mechanism by which RO reduced breast cancer cell viability, we treated BT-474 and MCF-7 cells for 24 h with 5, 10, or 20 μ M RO. Cells were then collected, and the levels of apoptosis and cell death were determined. RO significantly induced apoptosis and cell

death in both cell lines in a dose-dependent manner (Fig. 2a, b).

RO suppresses E-dependent proliferation of breast cancer cells in vitro and in vivo

Because E promotes proliferation of ER α -positive cells [1, 4], we examined whether RO reduces hormone-dependent

Fig. 3 RO suppresses Estradiol (E2)-induced proliferation of breast cancer cells. Breast cancer cells were treated with or without 10 nM E2 \pm 1, 5, or 10 μ M RO or 1 μ M ICI 182,780 (ICI) for 24 h in 5 % charcoal stripped serum, after which cell viability was determined by SRB assay. Values represent mean \pm SEM ($n = 6$). *Significantly different from control (set at 100 %); **significantly different from E2 ($P < 0.05$ using ANOVA)



proliferation of breast cancer cells. Using the anti-estrogen ICI 182,780 (which suppresses E-dependent cell proliferation [35, 36]) as our control ligand, we found that RO blocked E-dependent proliferation in four different breast cancer cell lines (Fig. 3 and data not shown for ZR-75 and MCF-7 cells). Furthermore, concentrations of RO that reduced E-induced cell proliferation also reduced cell viability in the absence of E.

Having demonstrated the effectiveness of RO in suppressing E-dependent breast cancer cell growth in vitro, we conducted studies to establish whether it had the same effect in vivo. We established estrogen-dependent BT-474 tumor xenografts in nude mice and began treatment with RO when the tumor volumes were approximately 100 mm³. Compared with controls, the tumor burden of animals administered RO was significantly reduced (Fig. 4a). Furthermore, animal weights were unaffected by RO treatment, indicating that the compound was non-toxic at the dose administered (Fig. 4b). No changes in blood chemistry or evidence of cataracts was observed, as determined by CBW, Head Pathologist IDDEX RADIL (data not shown).

In order to determine the effects of RO on levels of ER α and ER β protein expression in xenografts, we conducted immunohistochemical analysis of sections obtained from tumors collected at the end point in Fig. 4a. RO treatment resulted in significantly reduced levels of ER α within tumor tissue; however, ER β was more resilient to depletion (Fig. 4c). While there was a trend toward elevated levels of ER β in animals receiving 5 and 10 mg/kg, significance was attained in only the 10 mg/kg treatment group.

RO reduces levels of ER α protein and increases levels of ER β protein in breast cancer cells in vitro

Because RO prevented E-induced cell proliferation and caused a loss of ER α protein, we determined whether it affected levels of ER α and ER β in breast cancer cells in vitro. Pharmacological levels (25 μ M) of RO reduced ER α in three breast cancer cell lines in a time-dependent manner. RO was most effective against BT-474 cells; most of the receptor was lost after just 3 h of exposure in these cells, compared with 6 h for other cell lines (Fig. 5a, upper panel). The loss of ER α following treatment with RO for 3 h (BT-474) or 6 h (T47-D and MCF-7) was dose-dependent (1–25 μ M) (Fig. 5a, lower panel). Using BT-474 cells, we tested whether loss of ER α was due to proteasomal degradation. We found that this RO-mediated effect was dependent on ubiquitination, because treatment with MG-132, an inhibitor of proteasomal degradation, prevented receptor loss (Fig. 5b).

Importantly, when we examined ER β levels in RO-treated breast cancer cells, we found that in a short-term assay, ER β was increased in both BT-474 and T47-D cells in a time- and dose-dependent manner (Fig. 5c). RO also decreased expression of the survival protein Bcl-2 in breast cancer cells (Fig. 5d). Comparable results for changes in expression of ER α and ER β in response to RO treatment were obtained in a longer term assay (up to 48 h), using lower concentrations of RO (0.1–10 μ M) (Fig. 5e). Thus, our results indicate that treatment of breast cancer cells with RO leads to loss of ER α while simultaneously increasing ER β . Using BT-474 cells, we found that even lower (nM) doses of RO used for an extended period of time (7 days) degraded ER α and induced




Fig. 4 RO suppresses growth of E-dependent xenografts in nude mice. **a** Six-week-old nude mice received an estradiol slow-release (1.7 mg/60-days release) or placebo pellet by sc implantation 48 h prior to injection with 5×10^6 BT-474 breast cancer cells in Matrigel:DMEM/F12 (4:1; [v/v]) on both flanks. When tumor volumes reached approximately 100 mm³, animals were treated with RO (5 or 10 mg/kg) or the same volume of PBS (control) daily for 5 days, then every other day for five additional treatments by iv tail-vein injection; mice were given a final RO treatment 2 h before they were sacrificed. Values represent mean \pm SEM ($n = 5$).

*Significantly different from control ($P < 0.05$ using ANOVA). **b** Animal weight was monitored throughout the experiment. Arrows indicate duration of RO treatment. **c** Tumors were collected at end point as shown in **a** and processed for immunohistochemistry and data analysis as described in “Materials and Methods”. Insets represent negative controls and bars represent 50 μm. RO reduced ERα and increased ERβ staining within tumors. *Indicates $P < 0.05$ compared with controls, **denotes significant difference compared with control and treatment with 5 μM RO

ERβ (Fig. 5f, upper panel). In addition to ERβ, p21, an apoptosis and cell-cycle arrest protein, was also induced under these conditions (Fig. 5f, lower panel). p21 was also reduced in T47-D cells (data not shown), suggesting that the effects of RO are not confined to one cell line. Thus, loss of ERα and ERβ induction by RO in breast cancer cells appears to be off-target effects that occur in response to both low and high doses of the OSC inhibitor. Exposure of BT-474 or T47-D breast cancer cells to 25 μM RO did not affect levels of mRNA for either receptor (data not shown), indicating that RO-induced changes in ER levels were independent of RNA transcription.

Finally, we examined the effect of RO analogs, a different class of OSC inhibitor (U18666A), and HMG-CoA reductase inhibitors (statins) on ERα and ERβ levels. When BT-474 cells were exposed to 25 μM RO, three analogs of

RO, or U18666A, only the two RO analogs that were found to be most effective in reducing breast cancer cell viability (RO 48-8071 and RO 61-3479; Fig. 1a), caused a loss of ERα and increased ERβ (Fig. 5g). Of the two HMG-CoA reductase inhibitors tested (Simvastatin and Fluvastatin), only Fluvastatin decreased ERα levels. Neither statins elevated ERβ levels (Fig. 5h).

Modulation of ERβ activity modifies the anti-proliferative effects of RO on breast cancer cells

ERβ is known to play an anti-proliferative role in breast cancer cells [25–28, 37]. To determine whether induction of ERβ protein potentiates the anti-proliferative effects of RO, we treated BT-474 cells with RO in the presence




Fig. 5 RO decreases ERα and increases ERβ in breast cancer cells. **a** Breast cancer cells were treated with 0 (control; C), 1, 5, 10, or 25 μM RO for 3 or 6 h (BT-474) or 6 or 12 h (T47-D and MCF-7) in 5 % FBS DMEM:F12. *Upper panel*, all treatments with 25 μM RO; *lower panel*, BT-474 cells were treated for 3 h, and T47-D cells were treated for 6 h. **b** BT-474 cells were treated with 25 μM RO alone or in combination with 1 or 2.5 μM MG-132 (M) in 5 % FBS DMEM:F12 for 3 h. **c** Breast cancer cells were treated with 0 (control; C), 1, 5, 10, or 25 μM RO for 3 or 6 h (BT-474) or 6 or 12 h (T47-D and MCF-7) in 5 % FBS DMEM:F12. *Upper panel*, all treatments with 25 μM RO; *lower panel*, BT-474 cells were treated

for 3 h, and T47-D cells were treated for 6 h. **d** T47-D cells were treated with 0 (control; C), 5, 10, or 25 μM RO for 6 h in 5 % FBS DMEM:F12. **e** BT-474 cells were exposed to sub-pharmacological levels of RO (0.1–10 μM) for 48 h. **f** BT-474 cells were treated with 10 or 100 nM RO for 7 days with a media change every 48 h containing fresh RO. **g** BT-474 cells were treated with the indicated compounds at 25 μM for 3 h. **h** BT-474 cells were treated with 10 or 25 μM Simvastatin or Fluvastatin (or vehicle, C) for 3 h. For all panels, whole-cell extracts were subjected to Western blotting to analyze protein expression, and levels of β-actin were assessed as a protein loading control. All experiments were conducted at least twice

of an ERβ agonist DPN. DPN enhanced the effects of RO on reducing the viability of breast cancer cells (Fig. 6a), suggesting that activation of ERβ is partially responsible for RO-mediated effects on breast cancer cell viability. Incubation of BT-474 cells with the ERβ antagonist PHTPP blocked RO-mediated reduction of

cell viability (Fig. 6b), providing further evidence that ERβ plays a role in mediating the effects of RO on breast cancer cells. Interestingly, exposure of cells to PHTPP alone also increased cell viability. Similar observations were made with T47-D cells (data not shown).




Fig. 6 Modulation of ER β activity influences RO-mediated effects on breast cancer cell viability. **a** BT-474 cells were treated with 10 μ M RO \pm 1 μ M ER β agonist DPN or with 1 μ M DPN alone (dose taken from ref. [50]) for 48 h. Cell viability was determined by SRB assay. Values represent mean \pm SEM ($n = 6$). *Significantly different from control; **significantly different from RO-treatment and DPN-treatment groups ($P < 0.001$, ANOVA). **b** BT-474 cells were treated with 10 μ M RO \pm 10 nM or 100 nM ER β antagonist PHTPP (PH) for 24 h. Cell viability was determined by SRB assay. Values represent mean \pm SEM ($n = 6$). *Significantly increased compared with control (set at 100 %); **significantly decreased relative to control group; ***significantly different from RO-treatment group

Loss of ER β reduces the anti-proliferative effects of RO in breast cancer cells

Finally, we used siRNA knockdown studies to determine whether RO-induced increases in levels of ER β were responsible for anti-proliferative effects observed in breast cancer cells. ER β siRNA but not the scrambled siRNA control effectively knocked down ER β expression (Fig. 7a). Treatment with RO resulted in a loss of cell viability in both control samples and cells treated with scrambled siRNA. However, when cells were exposed to siRNA specific for ER β , RO was unable to reduce cell




Fig. 7 ER β knockdown blocks the anti-proliferative effects of RO in breast cancer cells. T47-D cells were transfected with 30 or 60 nM ER β siRNA (si-ER β) or scrambled siRNA (si-C) or transfection reagent alone (Control or C) for 72 h. **a** Whole-cell extracts were subjected to Western blotting to analyze ER β expression. Levels of β -actin were assessed as a protein loading control. **b** Cells transfected with 60 nM siRNA (or T47-D cells transfected with transfection reagent alone; parental cells) were treated with RO (10 μ M) or vehicle alone (C) for 48 h and cell viability determined by SRB assay. Values represent mean \pm SEM ($n = 6$). *Significantly different from vehicle control group; **significantly different from RO-treated samples in scrambled siRNA group and parental cell group ($P < 0.001$; one-way ANOVA)

viability to the same extent as it did in control and scrambled siRNA-treated cells (Fig. 7b). These findings support the idea that induction of ER β is at least partially involved in mediating the effects of RO on reducing cell viability in breast cancer cells.

Discussion

Hormone-dependent breast cancer is the most common type of clinically observed mammary cancer [1, 4, 6]. Although a number of anti-hormonal treatment strategies are currently employed to control progression of the disease, drug-resistant tumors that continue to express ER frequently emerge [1, 4]. As a consequence, studies are ongoing whose goal is to identify new compounds with the ability to control ER α -dependent proliferation in breast tissue and thereby prevent tumor progression. While conducting studies in breast cancer cells to determine the anti-proliferative capacity of cholesterol biosynthesis inhibitors, we discovered that analogs of RO, a class of compound that blocks OSC activity, also down-regulated ER α . Furthermore, RO compounds simultaneously up-regulated the druggable anti-proliferative protein ER β [25–28, 37], thus

negating the concerns that loss of ER α could lead to hormone-resistant tumors.

We examined the effects of four different RO analogs on ER α -positive breast cancer cell lines. All of them reduced the cell viability, with two particular compounds more potent than the others. We subsequently characterized the effects of RO 48-8071 (RO) as the lead compound on breast cancer cell proliferation and tumor development. RO effectively reduced tumor cell viability in short-term assays (IC₅₀ values between 6 and 12 μ M; SRB 48-h), while lower concentrations (nM) of RO significantly suppressed the viability of tumor cells in longer term (7 day) assays. We also observed that concentrations of RO up to 10 μ M had no effect on the viability of normal mammary cells, suggesting that its *in vitro* effects are specific to breast cancer cells. Consequently, we propose that since RO appears to be non-toxic to normal cells, it might be used to target tumors with little risk of patient toxicity. Subsequent *in vivo* studies provide evidence which further supports the use of RO as a therapeutic agent with little or no risk of toxic side effects. Although it is unlikely that RO binds directly to ER due to strict structural requirements for ER-ligand interactions, we will determine whether it binds directly to ER α and ER β in future studies using competition assays.

In order to compare the effects of RO with the more widely tested HMG-CoA reductase inhibitors (statins), we treated cells with Simvastatin and Fluvastatin, both of which effectively reduced breast cancer cell viability, though with less potency than RO. Our findings, therefore, suggest that RO is more effective than statins at inhibiting breast cancer cell proliferation.

RO suppressed E-induced proliferation of five breast cancer cell lines, including BT-474 cells, which are tamoxifen resistant and which express high levels of HER-2/neu. Tumors that are high in Her2/neu expression have poor prognosis [38, 39]. We administered RO to nude mice bearing BT-474 cell-derived xenografts grown in response to implanted E-containing pellets and observed suppression of tumor growth. This suggests that RO could be an effective means of suppressing cells that are resistant to anti-hormones, though this possibility remains to be tested. Studies are currently underway to determine whether administration of higher levels of RO might promote complete xenograft regression without toxicity.

Since RO suppressed the growth of E-dependent breast cancer cells, we conducted studies aimed at determining whether the OSC inhibitor affects ER α levels. We found that levels of ER α were indeed reduced dramatically in response to RO, in a time- and dose-dependent manner both *in vitro* and *in vivo*. BT-474 cells were most sensitive to RO, in accord with their sensitivity in SRB assays. Further *in vitro* studies showed that the proteasome

inhibitor MG-132 completely blocked receptor loss, indicating that RO induces proteasome-mediated receptor degradation. Ubiquitination has previously been shown to control ER degradation [40]. ER α mRNA synthesis was not reduced by RO treatment, suggesting that the loss of ER α is a post-transcriptional event. The term selective ER down-regulator or degrader has been used to describe the effect of therapeutic agents that degrade ER α , and RO seems to be another member of this class [41, 42]. Previously, the anti-estrogen ICI-182,780 has been shown to cause a similar loss of ER α in breast cancer cells [41]; however, its use in long-term treatment is restricted due to bone-related toxicities in post-menopausal women [43]. Further studies are needed with RO to determine its effect on bone after a long-term use.

Importantly, we found that as well as degrading ER α , pharmacological concentrations of RO concomitantly increased ER β levels *in vitro*. However, while induction of ER β was significant *in vitro*, its up-regulation was not as robust *in vivo*. This was most likely due to tumors being collected at the end point, several days after the initial treatment of nude mice bearing BT-474 xenografts. It is, therefore, likely that we missed the higher levels of ER β , which were subsequently lost when cells expressing elevated levels of ER β underwent apoptosis. However, this requires confirmation by collection of tumors a few days after initial treatment with RO and assessment of ER β induction. The consistent *in vitro* induction of ER β in various cell lines was most likely due to short-term exposure to the drug. In any event, the loss of ER α over time leads to a high ratio of ER β to ER α , a scenario which has been shown to inhibit tumor cell proliferation [44]. We further characterized the *in vitro* effect of RO by real-time PCR analysis and found that the OSC inhibitor did not affect levels of ER β mRNA. Thus, it would appear that RO likely stabilizes ER β protein over time. In future studies, we will examine in more detail just how RO influences ER β protein stability. Because BT-474 cells were most sensitive to the anti-proliferative effects of RO, we exposed this cell line to lower levels of RO and assessed ER β induction. Doses of RO as low as 100 nM induced ER β , while simultaneously degrading ER α , while in a 7-day assay, 10 nM RO completely eliminated ER α , while also inducing ER β (Fig. 5f).

Of the several RO analogs tested, the two that reduced breast cancer cell viability most effectively also potently reduced ER α levels while at the same time inducing ER β . Those that did not degrade ER α still induced ER β to some extent. Based on these findings, we conclude that increased ER β is the predominant off-target factor that accounts for loss of breast cancer cell viability following exposure to analogs of RO at least *in vitro*. Interestingly, HMG-CoA reductase inhibitors demonstrated a variable response;

while Simvastatin did not degrade ER α to the same degree as the two most effective RO analogs, Fluvastatin exerted a comparable effect in this regard. Neither Simvastatin nor Fluvastatin induced ER β . It is clear that the two classes of cholesterol biosynthesis inhibitor exert differential effects on the ratio of ER α and ER β in breast cancer cells. This ratio has been shown to be an important predictor of cell growth; a high ratio of ER α /ER β is proliferative, whereas increased expression of ER β is associated with loss of tumor cell proliferation [45–48].

To further confirm that ER β is at least partially responsible for loss of breast cancer cell viability, we blocked receptor activity using PHTPP, a selective ER β antagonist. PHTPP suppressed the anti-proliferative activity of RO in a dose-dependent manner. We further confirmed the important role played by ER β in reducing cell viability by exposing breast cancer cells to DPN, an ER β -specific agonist. When administered individually, both RO and DPN inhibited breast cancer cell viability. However, when a combination of the two compounds was given, their inhibitory effect was additive, an outcome that may be due to increased cellular levels of ER β in response to RO. Down-regulation of ER β by siRNA significantly reduced the anti-proliferative effects of RO, providing further evidence of the importance of ER β in mediating RO effects on breast cancer cell viability. It therefore appears likely that drugs that increase ER β activity in breast cancer cells could be made even more effective when administered in conjunction with RO. The development of therapeutic regimens using a combination of two agents might make it possible to manage disease using lower levels of both, reducing the likelihood of toxic side effects that result from current therapeutic modalities [49].

In summary, the data presented in this manuscript strongly suggest that, in addition to its ability to suppress cholesterol biosynthesis, the OSC inhibitor RO exerts a powerful anti-tumor effect by the off-target loss of ER α and induction of the anti-proliferative protein ER β . The loss of ER α but not ER β in vivo leads to a large increase in the ER β /ER α ratio, which could be responsible for tumor loss [43–48]. In addition, in vitro data show that ER β can promote some of the anti-tumor properties of RO. Thus, we propose that ER β is at least partially responsible for the observed suppression of breast cancer cell viability and suggest, therefore, that combination therapy using inhibitors of cholesterol biosynthesis (such as RO) together with commonly used chemotherapeutic drugs could prove beneficial as a means by which to suppress breast cancer progression. We are currently conducting studies to determine the effectiveness of such combination therapies.

Acknowledgments Supported by a Department of Defense Breast Cancer Program Grant W81XWH-12-1-0191, the National Institutes

of Health Grant R21 GM088517, and by a Faculty Research Grant from the University of Missouri, Columbia. SMH is the Zalk Missouri Professor of Tumor Angiogenesis. Funds to purchase the nanodrop instrument were provided through the generosity of numerous donors to the Ellis Fischel Cancer Center.

Conflict of interest JDA is an employee of F. Hoffmann-La Roche AG. All other authors declare that they have no conflict of interest.

Ethical standards The experiments comply with the current laws of the country in which they were performed (USA).

References

1. D'Abreo N, Hindenburg AA (2013) Sex hormone receptors in breast cancer. *Vitam Horm* 93:99–1331
2. Cordera F, Jordan VC (2006) Steroid receptors and their role in the biology and control of breast cancer growth. *Semin Oncol* 33:631–641
3. White R, Parker MG (1998) Molecular mechanisms of steroid hormone action. *Endocr Relat Cancer* 5:1–14
4. Pasqualini JR, Katzenellenbogen BS (eds) (1996) *Hormone-dependent cancer*. Marcel Dekker Inc., New York
5. Seeger H, Wallwiener D, Mueck AO (2008) Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. *Gynecol Endocrinol* 24:576–579
6. Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or Progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. *J Clin Oncol* 6:1076–1087
7. Harrell JC, Dye WW, Allred DC et al (2006) Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. *Cancer Res* 66:9308–9315
8. Hyder SM (2006) Sex-steroid regulation of vascular endothelial growth factor in breast cancer. *Endocr Relat Cancer* 13:667–687
9. Bailey ST, Shin H, Westerling T, Liu XS, Brown M (2012) Estrogen receptor prevents p53-dependent apoptosis in breast cancer. *Proc Natl Acad Sci USA* 109:18060–18065
10. Fernando RI, Wimalasena J (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. *Mol Biol Cell* 15:3266–3284
11. Schairer C, Lubin J, Troisi R et al (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA* 283:485–491
12. Li CI, Malone KE, Porter PL et al (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. *JAMA* 289:3254–3263
13. Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. *JAMA* 289:3243–3253
14. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. *J Natl Cancer Inst* 92:328–332
15. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. *Nat Rev Cancer* 9:631–643
16. Hiscox S, Morgan L, Green TP (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. *Breast Cancer Res Treat* 97:263–274

17. Bulun SE, Simpson ER (2008) Aromatase expression in women's cancers. *Adv Exp Med Biol* 630:112–132
18. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. *Science* 342:1094–1098
19. Wu Q, Ishikawa T, Sirianni R et al (2013) 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. *Cell Rep* 5:637–645
20. McTaggart SJ (2006) Isoprenylated proteins. *Cell Mol Life Sci* 63:255–267
21. Charlton-Menys V, Durrington PN (2007) Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. *Drugs* 67:11–16
22. Staedler D, Chapuis-Bernasconi C, Dehmlow H et al (2012) Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. *J Med Chem* 55:4990–5002
23. Thoma R, Schulz-Gasch T, D'Arcy B et al (2004) Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase. *Nature* 432:118–122
24. Grinter SZ, Liang Y, Huang SY, Hyder SM, Zou X (2011) An inverse docking approach for identifying new potential anti-cancer targets. *J Mol Graph Model* 29:795–799
25. Treeck O, Lattrich C, Springwald A, Ortmann O (2010) Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. *Breast Cancer Res Treat* 120:557–565
26. Paruthiyil S, Parmar H, Kerekatte V et al (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. *Cancer Res* 64:423–428
27. Warner M, Gustafsson JA (2010) The role of estrogen receptor beta (ERbeta) in malignant diseases—a new potential target for antiproliferative drugs in prevention and treatment of cancer. *Biochem Biophys Res Commun* 396:63–66
28. Deroo BJ, Buensuceno AV (2010) Minireview: estrogen receptor-beta: mechanistic insights from recent studies. *Mol Endocrinol* 24:1703–1714
29. Hartman J, Lindberg K, Morani A et al (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. *Cancer Res* 66:11207–11213
30. Dehmlow H, Aebi JD, Jolidon S et al (2003) Synthesis and structure-activity studies of novel orally active non-terpenoid 2,3-oxidosqualene cyclase inhibitors. *J Med Chem* 46:3354–3370
31. Liang Y, Besch-Williford C, Benakanakere I, Hyder SM (2007) Re-activation of p53 pathway inhibits growth of hormone-dependent human breast cancer cells in vitro and in vivo. *Int J Oncol* 31:777–784
32. Liang Y, Brekken RA, Hyder SM (2006) VEGF induces proliferation of breast cancer cells and counteracts the anti-proliferative activity of anti-hormones. *Endocr Relat Cancer* 13:905–919
33. Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM (2011) Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. *Breast Cancer Res Treat* 125:407–420
34. Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR, Hyder SM (2011) Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. *Cancer Prev Res* 4:1316–1324
35. Fan M, Bigsby RM, Nephew KP (2003) The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. *Mol Endocrinol* 17:356–365
36. Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T (2013) Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase. *PLoS ONE* 8:e60889
37. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. *Proc Natl Acad Sci USA* 101:1566–1571
38. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L et al (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. *J Clin Oncol* 10:599–605
39. Agrup M, Stål O, Olsen K, Wingren S (2000) C-erbB-2 overexpression and survival in early onset breast cancer. *Breast Cancer Res Treat* 63:23–29
40. Nawaz Z, Lonard DM, Dennis AP et al (1999) Proteasome-dependent degradation of the human estrogen receptor. *Proc Natl Acad Sci USA* 96:1858–1862
41. Robertson JF (2001) ICI 182,780 (Fulvestrant)—the first oestrogen receptor down-regulator—current clinical data. *Br J Cancer* 85(Suppl 2):11–14
42. Wardell SE, Marks JR, McDonnell DP (2011) The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. *Biochem Pharmacol* 82:122–130
43. Gallagher A, Chambers TJ, Tobias JH (1993) The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. *Endocrinology* 133:2787–2791
44. Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Ström A, Gustafsson JA, Rietjens I, Murk AJ (2008) Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. *Toxicol Sci* 105:303–311
45. Lindberg MK, Movérare S, Skrtic S et al (2003) Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a “ying yang” relationship between ER-alpha and ERbeta in mice. *Mol Endocrinol* 17:203–208
46. Williams C, Edvardsson K, Lewandowski SA et al (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. *Oncogene* 27:1019–1032
47. Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. *Nat Rev Cancer* 11:597–608
48. Madeira M, Mattar A, Logullo AF, Soares FA, Gebrim LH (2013) Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness—a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. *BMC Cancer* 13:425
49. Wyld DK, Chester JD, Perren TJ (1998) Endocrine aspects of the clinical management of breast cancer—current issues. *Endocr Relat Cancer* 5:97–110
50. Chen S, Bangaru ML, Sneade L et al (2009) Epidermal growth factor receptor cross-talks with ligand-occupied estrogen receptor-alpha to modulate both lactotroph proliferation and prolactin gene expression. *Am J Physiol Endocrinol Metab* 297:331–339

Poster Presentation

Mafuvadze, B., Liang, Y., Hyder, S. M. (2014) Oxidosqualene Cyclase Inhibitor Suppresses Transcriptional Activity of Estrogen Receptor- α in Human Breast Cancer Cells. 16th International Congress of Endocrinology and the Endocrine Society's 96th Annual Meeting and Expo, Chicago, IL. Abstract SAT-0279

Oxidosqualene Cyclase Inhibitor Suppresses Transcriptional Activity of Estrogen Receptor- α in Human Breast Cancer Cells

Benford Mafuvadze, PhD, Yayun Liang, PhD and Salman M. Hyder, PhD

Department of Biomedical Sciences, University of Missouri-Columbia, USA

Cholesterol is the synthetic precursor of steroid hormones such as estrogens and progestins, which control the growth of many types of human breast cancer. Enzymes responsible for converting cholesterol into steroid hormones are present within breast tumor cells, resulting in local estrogen production. This could lead to tumors becoming resistant to anti-estrogen therapy. In this study we determined whether oxidosqualene cyclase (OSC), an enzyme in the cholesterol biosynthetic pathway, might be targeted to suppress progression of breast cancer cells. Using in silico analysis we previously identified the OSC inhibitor RO 48-8071 (RO), as a potential ligand which could be used to control the progression of estrogen receptor-alpha positive (ER α +ve) breast cancer cells. However, real-time PCR analysis of mRNA from human breast cancer biopsies obtained at various stages of disease did not identify significant differences in OSC expression between tumor tissues or between tumor and normal mammary cells. Nevertheless, since RO reduced tumor cell viability, we examined other potential targets by which it might exert its anti-proliferative effects. Since the growth of hormone-responsive tumors is ER α -dependent, we determined whether RO affected ER α . Using non-human mammalian cells engineered to express human ER α protein and an ER α -responsive luciferase promoter (Indigo Biosciences) we found that RO inhibited 17 β -estradiol (E2)-induced ER α responsive luciferase activity. Inhibition was dose-dependent, with an IC₅₀ of approximately 10 μ M under conditions that were non-toxic to the cells. In order to determine whether RO influenced the biological activity of ER α , we selected treatment conditions (5 μ M RO, 16-18h) that did not affect cell viability or influence ER α protein levels. We then treated BT-474 breast cancer cells with 10 nM E2 \pm 5 μ M RO for 16-18 h and used Western blotting to measure levels of PR, an estrogen responsive gene. RO reduced PR levels in BT-474 cells, confirming that it blocks ER α activity in tumor cells. Real-time PCR and Western blotting revealed no effect of RO on levels of either ER α mRNA or protein. Our findings demonstrate that an important means by which RO suppresses hormone-dependent growth of breast cancer cells is through its ability to arrest the biological activity of ER α . We suggest therefore that our studies support further investigation of RO as a potential therapeutic agent for use against hormone-dependent breast cancers.

Support: Supported by a Dept of Defense Breast Cancer Pgm grant W81XWH-12-1-0191, and by a COR grant from the University of Missouri, Columbia. SMH is the Zalk Missouri Professor of Tumor Angiogenesis.